Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
This research aims to understand acute malnutrition in infants younger than 6 months admitted to pediatric or perinatology wards in hospitals across Indonesia. The study will observe how common acute malnutrition is in this age group and investigate the outcomes of nutrition therapy, including recovery, growth improvement, complications, and death. It also seeks to identify factors linked to successful nutrition treatment based on the 2023 WHO criteria. The study is observational and will not provide experimental treatments. Instead, it will collect detailed measurements of infants weight, length, head circumference, and mid-upper arm circumference at baseline, day 3, day 7, and weekly until hospital discharge. Information about birth history, feeding, illnesses, and nutrition therapy provided by treating doctors will be recorded. Data will be securely stored in a shared electronic database to ensure consistency across multiple hospitals participating in the network. Participants will be infants under 6 months diagnosed with acute malnutrition. Researchers will gather clinical data, anthropometric measurements, feeding details, and lab results during hospital stay. The study will monitor nutritional status changes up to 24 weeks or until discharge and track outcomes such as mortality. Results will help develop evidence-based feeding guidelines and improve clinical care for malnourished infants in Indonesia.
Actively Recruiting
Researchers are evaluating the effects of once-daily versus twice-daily dosing of ramipril on kidney function in patients who have chronic kidney disease CKD along with heart failure with reduced ejection fraction HFrEF. This study aims to understand how these dosing schedules influence important factors like plasma renin activity, inflammation markers, oxidative stress, and kidney health over a 30-day treatment period. It addresses the current uncertainty in treatment guidelines about the best dosing frequency for ramipril in these patients. Participants are randomly assigned to receive either 10 mg of ramipril once daily or 5 mg twice daily, both for 30 days. This is a double-blind study, meaning neither participants nor researchers know who receives which dosing schedule, to fairly compare the effects. The study focuses on measuring changes in biomarkers such as plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C to assess kidney function and related biological activity. During the study, patients will be monitored closely with laboratory tests to measure kidney function and inflammation at the start and after 30 days of treatment. Blood pressure and other safety indicators will also be checked. The main goal is to determine which dosing schedule better supports kidney health and reduces harmful biological changes in this patient group. The trial lasts 30 days, and participants health status and any side effects will be carefully observed throughout this period.